De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Luye Pharma Group Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dian Bo Liu

Algemeen directeur

CN¥4.2m

Totale compensatie

Percentage CEO-salaris	75.1%
Dienstverband CEO	21.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	12.8yrs
Gemiddelde ambtstermijn bestuur	10.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dian Bo Liu's beloning veranderd ten opzichte van Luye Pharma Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	CN¥770m
Mar 31 2024	n/a	n/a	CN¥652m
Dec 31 2023	CN¥4m	CN¥3m	CN¥533m
Sep 30 2023	n/a	n/a	CN¥495m
Jun 30 2023	n/a	n/a	CN¥458m
Mar 31 2023	n/a	n/a	CN¥531m
Dec 31 2022	CN¥3m	CN¥3m	CN¥605m
Sep 30 2022	n/a	n/a	CN¥190m
Jun 30 2022	n/a	n/a	-CN¥224m
Mar 31 2022	n/a	n/a	-CN¥179m
Dec 31 2021	CN¥4m	CN¥3m	-CN¥134m
Sep 30 2021	n/a	n/a	CN¥210m
Jun 30 2021	n/a	n/a	CN¥554m
Mar 31 2021	n/a	n/a	CN¥630m
Dec 31 2020	CN¥5m	CN¥4m	CN¥707m
Sep 30 2020	n/a	n/a	CN¥955m
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥4m	CN¥3m	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥4m	CN¥3m	CN¥981m

Compensatie versus markt: De totale vergoeding ($USD 595.65K ) Dian Bo } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.58M ).

Compensatie versus inkomsten: De vergoeding van Dian Bo is het afgelopen jaar met meer dan 20% gestegen.

CEO

Dian Bo Liu (58 yo)

21.3yrs

Tenure

CN¥4,180,000

Compensatie

Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dian Bo Liu	Co-Founder	21.3yrs	CN¥4.18m	geen gegevens
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.3yrs	CN¥3.09m	geen gegevens
Hui Xian Yuan	Co-Founder & Executive Director	no data	CN¥1.46m	geen gegevens
Yuan Yuan Zhu	Executive Director	no data	CN¥1.50m	geen gegevens
Yuan Chong Liu	Chief Financial Officer	12.8yrs	geen gegevens	geen gegevens
Mei Yi Lee	Company Secretary	3.8yrs	geen gegevens	geen gegevens

12.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LUP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dian Bo Liu	Co-Founder	21.3yrs	CN¥4.18m	geen gegevens
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.3yrs	CN¥3.09m	geen gegevens
Hui Xian Yuan	Co-Founder & Executive Director	21.3yrs	CN¥1.46m	geen gegevens
Yuan Yuan Zhu	Executive Director	10.6yrs	CN¥1.50m	geen gegevens
Yuk Lam Lo	Independent Non-Executive Director	10.3yrs	CN¥269.00k	geen gegevens
Man Kit Leung	Independent Non-Executive Director	10.3yrs	CN¥322.00k	geen gegevens
Rui Lin Song	Non-Executive Director	7.6yrs	CN¥269.00k	geen gegevens
Sze Chung Choy	Independent Non-Executive Director	10.3yrs	CN¥269.00k	geen gegevens
Huaqiao Zhang	Independent Non-Executive Director	10.3yrs	CN¥269.00k	geen gegevens
Dong Lyu	Non-Executive Director	less than a year	geen gegevens	geen gegevens
Lian Xia	Independent Non-Executive Director	1.4yrs	CN¥162.00k	geen gegevens

10.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LUP zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.3 jaar).

Luye Pharma Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Less than half of directors are independent

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Less than half of directors are independent

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

Full year 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in FY 2022)

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 21% undervalued after recent price drop

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.039 loss in FY 2021)

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection

Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States

Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)

Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in China

Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United Kingdom

Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015

Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.S

Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in China

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in China

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.44 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.46 in FY 2019)

Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 Injection

Luye Pharma Group Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021